Cover Image
市場調查報告書

EpiCast Report:慢性B型肝炎 - 到2024年的流行病學預測

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 351348
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:慢性B型肝炎 - 到2024年的流行病學預測 EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
出版日期: 2015年12月24日 內容資訊: 英文 55 Pages
簡介

全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、中國),慢性B型肝炎和確診的患者數,預計從2014年的10,557,407人增加到2024年的10,861,653人。

本報告提供全球主要8個國家的慢性B型肝炎調查分析、疾病的背景、危險因素和合併症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 慢性B型肝炎的流行病學預測
    • 確診的患者數
    • 確診的患者數 (各年齡)
    • 確診的患者數 (性別)
    • 確診的患者數 (年齡標準化)等
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER112-15

The Hepatitis B Virus (HBV) can cause both acute and chronic liver disease. HBV is typically transmitted through contact with infectious blood or bodily fluid, including vertical transmission from mother to child at birth and transmission via sexual intercourse. Risk factors of chronic hepatitis B (CHB) include unprotected sex with an infected partner, men who have sex with men (MSM), intravenous drug injection (IDU), and a previous history of a sexually transmitted disease (STD). CHB has a well-established comorbidity association with hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection, human immunodeficiency virus (HIV) infection, and alcohol abuse. The disease often starts as asymptomatic in the acute infection phase, with symptoms beginning to present 30 to 180 days from infection. When symptoms develop, they present as nausea, vomiting, loss of appetite, flu-like symptoms, and jaundice. Severe cases of HBV infection increase the risk of developing liver cancer and cirrhosis.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of chronic hepatitis B (CHB) in the 8MM, from 10,557,407 cases in 2014 to 10,861,653 cases in 2024, at an Annual Growth Rate (AGR) of 0.29% in the forecast period. The distribution of diagnosed prevalent chronic hepatitis B cases in the 8MM was greater in men (7,379,948 cases, 69.90% in 2014) than in women (3,177,459 cases, 30.10% in 2014). This skew towards men was found to be consistent across all markets.

GlobalData's epidemiological forecast for the diagnosed prevalent cases of CHB are supported by age- and sex-specific data obtained from country-specific studies published in peer-reviewed journals, in which the study populations are representative of the general population in the respective markets. The diagnosed prevalent cases are further segmented into ALT level, HBV DNA level, HBeAg status, cirrhosis status, and co-infection with hepatitis C and HIV, thus providing a comprehensive view of the characteristics of CHB patients in the 8MM. Additionally, GlobalData epidemiologists used the same methodology across the 8MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of CHB in these markets.

Scope

  • The Chronic Hepatitis B (CHB) EpiCast Report provides an overview of the risk factors and global trends of CHB in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of CHB segmented by sex and in these markets. The diagnosed prevalent cases of CHB are further segmented by hepatitis B virus (HBV) DNA level (<2000IU/mL, 2,000-20,000IU/mL, and >20,000IU/mL in the US and the 5EU, and <1000IU/mL, 1,000-10,000IU/mL, and >10,000IU/mL in Japan and China), alanine aminotransferase (ALT) level (=2 upper limit of normal [ULN] 2-5ULN and >5ULN), hepatitis e surface antigen (HBeAg) status, and the liver cirrhosis status.
  • The CHB epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The CHB EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CHB market.
  • Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.
  • Identify the percentage of CHB diagnosed prevalent cases by various clinical segmentations.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of Chronic Hepatitis B (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of Chronic Hepatitis B
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B
    • 3.5.4. Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B
    • 3.5.5. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level
    • 3.5.6. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level
    • 3.5.7. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status
    • 3.5.8. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status
    • 3.5.9. Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Chronic Hepatitis B
  • Table 2: 8MM, Sources Used for the Diagnosed Prevalent Cases Forecast of Chronic Hepatitis B in the 8MM
  • Table 3: 8MM, Sources Used for HBV DNA Level
  • Table 4: 8MM, Sources Used for Chronic Hepatitis B by ALT Level
  • Table 5: 8MM, Sources Used for Chronic Hepatitis B HBeAg Status
  • Table 6: 8MM, Sources Used for Cirrhosis Status
  • Table 7: 8MM, Sources Used for HIV Co-infection
  • Table 8: 8MM, Sources Used for Hepatitis C Co-infection
  • Table 9: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, All Ages, Select Years, 2014-2024
  • Table 10: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N (Row %), 2014
  • Table 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N, 2014
  • Table 12: US and 5EU, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 13: Japan and China, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 14: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 15: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 16: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented Cirrhosis Status, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 17: 8MM, Diagnosed Prevalent Chronic Hepatitis B Cases Segmented by Co-infection with HIV and Hepatitis C, Both Sexes, Ages ≥18 Years, N (% of Diagnosed Chronic Hepatitis B Cases), 2014

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, Ages ≥18 Years, Select Years, 2014-2024
  • Figure 2: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, Both Sexes, N, 2014
  • Figure 3: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N, 2014
  • Figure 4: 8MM, Age-Standardised Diagnosed Prevalence of Chronic Hepatitis B, Ages ≥18 Years, 2014
Back to Top